Abevmy Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high cost burden of originator biologics, rising global cancer incidence, proven efficacy of vegf inhibition therapies, increasing hospital oncology drug utilization, early biosimilar policy frameworks.

The growth in the forecast period can be attributed to expanding biosimilar penetration in oncology, growing demand for affordable cancer therapies, increasing government support for biosimilars, rising oncology patient pool, broader tender based procurement adoption. Major trends in the forecast period include increasing adoption of bevacizumab biosimilars, rising use in cost sensitive oncology treatments, growing preference for hospital based biosimilar switching, expansion of anti angiogenic therapies in oncology, greater regulatory support for biosimilar approvals.

The growing prevalence of cancer is expected to drive the expansion of the Abevmy market in the coming years. Cancer development is influenced by multiple factors, broadly categorized into lifestyle choices, environmental exposures, and genetic predisposition. The rising incidence of cancer can be attributed to factors such as an aging population, lifestyle changes including unhealthy diets, physical inactivity, smoking, and alcohol consumption, as well as increased exposure to environmental carcinogens. Abevmy functions by inhibiting vascular endothelial growth factor (VEGF), thereby reducing the formation of blood vessels that supply tumors with oxygen and nutrients, which limits tumor growth and spread. For example, in February 2025, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, an estimated 9,550 children aged 0 to 14 years and 5,140 adolescents aged 15 to 19 years were projected to be diagnosed with cancer in 2025, with approximately 1,050 children and 600 adolescents expected to die from the disease. Consequently, the increasing burden of cancer is contributing to the growth of the Abevmy market.

Companies operating in the Abevmy (bevacizumab biosimilar) market are increasingly focusing on the development of biosimilars to improve access to affordable biologic therapies, address unmet medical needs, and reduce overall healthcare expenditures. Biosimilars are designed to offer cost-effective alternatives to originator biologics while maintaining comparable safety, efficacy, and quality. For instance, in June 2023, Enzene Biosciences, an India-based biotechnology company specializing in biosimilars and biologics CDMO services, launched a bevacizumab biosimilar to Avastin. The product is manufactured at Enzene’s Pune facility using a patented continuous manufacturing process that significantly reduces production costs and carbon emissions. This recombinant humanized monoclonal IgG1 antibody targets VEGF by binding to it and blocking receptor interaction, thereby inhibiting tumor growth and the proliferation of cancer cells.

In February 2024, Biocon Biologics, an India-based manufacturer of Abevmy, a biosimilar of bevacizumab (Avastin), entered into a partnership with Sandoz Australia to broaden the reach of its oncology biosimilars. Through this collaboration, Biocon Biologics aims to leverage Sandoz Australia’s established commercial and distribution network to expand access to biosimilar cancer treatments across the Australian market. Sandoz Australia is an Australia-based provider of generic medicines and biosimilars, supplying a broad portfolio of products to hospitals, clinics, and pharmacies.

Major companies operating in the abevmy market are Biocon Biologics Ltd., Viatris Inc.

North America was the largest region in the abevmy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abevmy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the abevmy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the abevmy market by increasing costs related to imported biologic manufacturing inputs and cold chain logistics. These impacts are most visible in biosimilar supply chains serving oncology hospitals across asia pacific and europe, where cross border trade is significant. Higher tariffs have placed pressure on tender pricing and hospital procurement budgets. At the same time, tariffs are encouraging regional biosimilar manufacturing and local sourcing, supporting long term supply security and cost stability.

The abevmy market research report is one of a series of new reports that provides abevmy market statistics, including abevmy industry global market size, regional shares, competitors with a abevmy market share, detailed abevmy market segments, market trends and opportunities, and any further data you may need to thrive in the abevmy industry. This abevmy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Abevmy is a biosimilar form of the cancer drug bevacizumab, developed to provide a more cost-effective option while retaining comparable safety and effectiveness. It functions by targeting vascular endothelial growth factor (VEGF), a protein that promotes the formation of blood vessels supplying tumors with oxygen and nutrients. By blocking VEGF, Abevmy inhibits angiogenesis, thereby restricting tumor growth and spread.

The main dosage strengths available in the Abevmy market are 100 mg and 400 mg. The 100 mg dose of Abevmy is a specific formulation intended for patients undergoing treatment for various types of cancer. The conditions treated include cancer and eye diseases, and the product is distributed through channels such as direct tender, hospital pharmacies, retail pharmacies, and online pharmacies. The end users include hospitals, cancer supportive care centers, academic and research institutes, and home healthcare settings.

The abevmy market consists of sales of intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.